Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) a...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) Jg. 51; H. 14; S. 1989 - 2007 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.09.2015
|
| Schlagworte: | |
| ISSN: | 0959-8049, 1879-0852, 1879-0852 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cSCC diagnosis and management, based on a critical review of the literature, existing guidelines and the expert’s experience. The diagnosis of cSCC is primarily based on clinical features. A biopsy or excision and histologic confirmation should be performed in all clinically suspicious lesions in order to facilitate the prognostic classification and correct management of cSCC. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. The EDF–EADO–EORTC consensus group recommends a standardised minimal margin of 5mm even for low-risk tumours. For tumours, with histological thickness of >6mm or in tumours with high risk pathological features, e.g. high histological grade, subcutaneous invasion, perineural invasion, recurrent tumours and/or tumours at high risk locations an extended margin of 10mm is recommended. As lymph node involvement by cSCC increases the risk of recurrence and mortality, a lymph node ultrasound is highly recommended, particularly in tumours with high-risk characteristics. In the case of clinical suspicion or positive findings upon imaging, a histologic confirmation should be sought either by fine needle aspiration or by open lymph node biopsy. In large infiltrating tumours with signs of involvement of underlying structures, additional imaging tests, such as CT or MRI imaging may be required to accurately assess the extent of the tumour and the presence of metastatic spread. Current staging systems for cSCC are not optimal, as they have been developed for head and neck tumours and lack extensive validation or adequate prognostic discrimination in certain stages with heterogeneous outcome measures. Sentinel lymph node biopsy has been used in patients with cSCC, but there is no conclusive evidence of its prognostic or therapeutic value. In the case of lymph node involvement by cSCC, the preferred treatment is a regional lymph node dissection. Radiation therapy represents a fair alternative to surgery in the non-surgical treatment of small cSCCs in low risk areas. It generally should be discussed either as a primary treatment for inoperable cSCC or in the adjuvant setting. Stage IV cSCC can be responsive to various chemotherapeutic agents; however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, should be discussed as second line treatments after mono- or polychemotherapy failure and disease progression or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A close follow-up plan is recommended based on risk assessment of locoregional recurrences, metastatic spread or development of new lesions. |
|---|---|
| AbstractList | Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cSCC diagnosis and management, based on a critical review of the literature, existing guidelines and the expert's experience. The diagnosis of cSCC is primarily based on clinical features. A biopsy or excision and histologic confirmation should be performed in all clinically suspicious lesions in order to facilitate the prognostic classification and correct management of cSCC. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. The EDF-EADO-EORTC consensus group recommends a standardised minimal margin of 5 mm even for low-risk tumours. For tumours, with histological thickness of >6 mm or in tumours with high risk pathological features, e.g. high histological grade, subcutaneous invasion, perineural invasion, recurrent tumours and/or tumours at high risk locations an extended margin of 10 mm is recommended. As lymph node involvement by cSCC increases the risk of recurrence and mortality, a lymph node ultrasound is highly recommended, particularly in tumours with high-risk characteristics. In the case of clinical suspicion or positive findings upon imaging, a histologic confirmation should be sought either by fine needle aspiration or by open lymph node biopsy. In large infiltrating tumours with signs of involvement of underlying structures, additional imaging tests, such as CT or MRI imaging may be required to accurately assess the extent of the tumour and the presence of metastatic spread. Current staging systems for cSCC are not optimal, as they have been developed for head and neck tumours and lack extensive validation or adequate prognostic discrimination in certain stages with heterogeneous outcome measures. Sentinel lymph node biopsy has been used in patients with cSCC, but there is no conclusive evidence of its prognostic or therapeutic value. In the case of lymph node involvement by cSCC, the preferred treatment is a regional lymph node dissection. Radiation therapy represents a fair alternative to surgery in the non-surgical treatment of small cSCCs in low risk areas. It generally should be discussed either as a primary treatment for inoperable cSCC or in the adjuvant setting. Stage IV cSCC can be responsive to various chemotherapeutic agents; however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, should be discussed as second line treatments after mono- or polychemotherapy failure and disease progression or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A close follow-up plan is recommended based on risk assessment of locoregional recurrences, metastatic spread or development of new lesions.Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cSCC diagnosis and management, based on a critical review of the literature, existing guidelines and the expert's experience. The diagnosis of cSCC is primarily based on clinical features. A biopsy or excision and histologic confirmation should be performed in all clinically suspicious lesions in order to facilitate the prognostic classification and correct management of cSCC. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. The EDF-EADO-EORTC consensus group recommends a standardised minimal margin of 5 mm even for low-risk tumours. For tumours, with histological thickness of >6 mm or in tumours with high risk pathological features, e.g. high histological grade, subcutaneous invasion, perineural invasion, recurrent tumours and/or tumours at high risk locations an extended margin of 10 mm is recommended. As lymph node involvement by cSCC increases the risk of recurrence and mortality, a lymph node ultrasound is highly recommended, particularly in tumours with high-risk characteristics. In the case of clinical suspicion or positive findings upon imaging, a histologic confirmation should be sought either by fine needle aspiration or by open lymph node biopsy. In large infiltrating tumours with signs of involvement of underlying structures, additional imaging tests, such as CT or MRI imaging may be required to accurately assess the extent of the tumour and the presence of metastatic spread. Current staging systems for cSCC are not optimal, as they have been developed for head and neck tumours and lack extensive validation or adequate prognostic discrimination in certain stages with heterogeneous outcome measures. Sentinel lymph node biopsy has been used in patients with cSCC, but there is no conclusive evidence of its prognostic or therapeutic value. In the case of lymph node involvement by cSCC, the preferred treatment is a regional lymph node dissection. Radiation therapy represents a fair alternative to surgery in the non-surgical treatment of small cSCCs in low risk areas. It generally should be discussed either as a primary treatment for inoperable cSCC or in the adjuvant setting. Stage IV cSCC can be responsive to various chemotherapeutic agents; however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, should be discussed as second line treatments after mono- or polychemotherapy failure and disease progression or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A close follow-up plan is recommended based on risk assessment of locoregional recurrences, metastatic spread or development of new lesions. Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cSCC diagnosis and management, based on a critical review of the literature, existing guidelines and the expert's experience. The diagnosis of cSCC is primarily based on clinical features. A biopsy or excision and histologic confirmation should be performed in all clinically suspicious lesions in order to facilitate the prognostic classification and correct management of cSCC. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. The EDF-EADO-EORTC consensus group recommends a standardised minimal margin of 5 mm even for low-risk tumours. For tumours, with histological thickness of >6 mm or in tumours with high risk pathological features, e.g. high histological grade, subcutaneous invasion, perineural invasion, recurrent tumours and/or tumours at high risk locations an extended margin of 10 mm is recommended. As lymph node involvement by cSCC increases the risk of recurrence and mortality, a lymph node ultrasound is highly recommended, particularly in tumours with high-risk characteristics. In the case of clinical suspicion or positive findings upon imaging, a histologic confirmation should be sought either by fine needle aspiration or by open lymph node biopsy. In large infiltrating tumours with signs of involvement of underlying structures, additional imaging tests, such as CT or MRI imaging may be required to accurately assess the extent of the tumour and the presence of metastatic spread. Current staging systems for cSCC are not optimal, as they have been developed for head and neck tumours and lack extensive validation or adequate prognostic discrimination in certain stages with heterogeneous outcome measures. Sentinel lymph node biopsy has been used in patients with cSCC, but there is no conclusive evidence of its prognostic or therapeutic value. In the case of lymph node involvement by cSCC, the preferred treatment is a regional lymph node dissection. Radiation therapy represents a fair alternative to surgery in the non-surgical treatment of small cSCCs in low risk areas. It generally should be discussed either as a primary treatment for inoperable cSCC or in the adjuvant setting. Stage IV cSCC can be responsive to various chemotherapeutic agents; however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, should be discussed as second line treatments after mono- or polychemotherapy failure and disease progression or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A close follow-up plan is recommended based on risk assessment of locoregional recurrences, metastatic spread or development of new lesions. Abstract Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cSCC diagnosis and management, based on a critical review of the literature, existing guidelines and the expert’s experience. The diagnosis of cSCC is primarily based on clinical features. A biopsy or excision and histologic confirmation should be performed in all clinically suspicious lesions in order to facilitate the prognostic classification and correct management of cSCC. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. The EDF–EADO–EORTC consensus group recommends a standardised minimal margin of 5 mm even for low-risk tumours. For tumours, with histological thickness of >6 mm or in tumours with high risk pathological features, e.g. high histological grade, subcutaneous invasion, perineural invasion, recurrent tumours and/or tumours at high risk locations an extended margin of 10 mm is recommended. As lymph node involvement by cSCC increases the risk of recurrence and mortality, a lymph node ultrasound is highly recommended, particularly in tumours with high-risk characteristics. In the case of clinical suspicion or positive findings upon imaging, a histologic confirmation should be sought either by fine needle aspiration or by open lymph node biopsy. In large infiltrating tumours with signs of involvement of underlying structures, additional imaging tests, such as CT or MRI imaging may be required to accurately assess the extent of the tumour and the presence of metastatic spread. Current staging systems for cSCC are not optimal, as they have been developed for head and neck tumours and lack extensive validation or adequate prognostic discrimination in certain stages with heterogeneous outcome measures. Sentinel lymph node biopsy has been used in patients with cSCC, but there is no conclusive evidence of its prognostic or therapeutic value. In the case of lymph node involvement by cSCC, the preferred treatment is a regional lymph node dissection. Radiation therapy represents a fair alternative to surgery in the non-surgical treatment of small cSCCs in low risk areas. It generally should be discussed either as a primary treatment for inoperable cSCC or in the adjuvant setting. Stage IV cSCC can be responsive to various chemotherapeutic agents; however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, should be discussed as second line treatments after mono- or polychemotherapy failure and disease progression or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A close follow-up plan is recommended based on risk assessment of locoregional recurrences, metastatic spread or development of new lesions. Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cSCC diagnosis and management, based on a critical review of the literature, existing guidelines and the expert’s experience. The diagnosis of cSCC is primarily based on clinical features. A biopsy or excision and histologic confirmation should be performed in all clinically suspicious lesions in order to facilitate the prognostic classification and correct management of cSCC. The first line treatment of cutaneous SCC is complete surgical excision with histopathological control of excision margins. The EDF–EADO–EORTC consensus group recommends a standardised minimal margin of 5mm even for low-risk tumours. For tumours, with histological thickness of >6mm or in tumours with high risk pathological features, e.g. high histological grade, subcutaneous invasion, perineural invasion, recurrent tumours and/or tumours at high risk locations an extended margin of 10mm is recommended. As lymph node involvement by cSCC increases the risk of recurrence and mortality, a lymph node ultrasound is highly recommended, particularly in tumours with high-risk characteristics. In the case of clinical suspicion or positive findings upon imaging, a histologic confirmation should be sought either by fine needle aspiration or by open lymph node biopsy. In large infiltrating tumours with signs of involvement of underlying structures, additional imaging tests, such as CT or MRI imaging may be required to accurately assess the extent of the tumour and the presence of metastatic spread. Current staging systems for cSCC are not optimal, as they have been developed for head and neck tumours and lack extensive validation or adequate prognostic discrimination in certain stages with heterogeneous outcome measures. Sentinel lymph node biopsy has been used in patients with cSCC, but there is no conclusive evidence of its prognostic or therapeutic value. In the case of lymph node involvement by cSCC, the preferred treatment is a regional lymph node dissection. Radiation therapy represents a fair alternative to surgery in the non-surgical treatment of small cSCCs in low risk areas. It generally should be discussed either as a primary treatment for inoperable cSCC or in the adjuvant setting. Stage IV cSCC can be responsive to various chemotherapeutic agents; however, there is no standard regimen. EGFR inhibitors such as cetuximab or erlotinib, should be discussed as second line treatments after mono- or polychemotherapy failure and disease progression or within the framework of clinical trials. There is no standardised follow-up schedule for patients with cSCC. A close follow-up plan is recommended based on risk assessment of locoregional recurrences, metastatic spread or development of new lesions. |
| Author | Middleton, Mark R. Becker, Jürgen C. Pehamberger, Hubert Zalaudek, Iris Bastholt, Lars Malvehy, Josep Peris, Ketty Saiag, Philippe Testori, Alessandro Grob, Jean-Jacques Garbe, Claus Stratigos, Alexander Lebbe, Celeste del Marmol, Veronique |
| Author_xml | – sequence: 1 givenname: Alexander surname: Stratigos fullname: Stratigos, Alexander email: alstrat@hol.gr organization: Department of Dermatology, University of Athens, A. Sygros Hospital, Athens, Greece – sequence: 2 givenname: Claus surname: Garbe fullname: Garbe, Claus organization: University Department of Dermatology, Tuebingen, Germany – sequence: 3 givenname: Celeste surname: Lebbe fullname: Lebbe, Celeste organization: University Department of Dermatology, Saint-Louis Hospital, Paris, France – sequence: 4 givenname: Josep surname: Malvehy fullname: Malvehy, Josep organization: Department of Dermatology, Hospital Clinic of Barcelona, IDIBAPS and CIBER de enfermedades raras, Spain – sequence: 5 givenname: Veronique surname: del Marmol fullname: del Marmol, Veronique organization: University Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium – sequence: 6 givenname: Hubert surname: Pehamberger fullname: Pehamberger, Hubert organization: University Department of Dermatology, Vienna, Austria – sequence: 7 givenname: Ketty surname: Peris fullname: Peris, Ketty organization: Istituto di Clinica Dermosifilopatica, Università Cattolica del Sacro cuore, Rome, Italy – sequence: 8 givenname: Jürgen C. surname: Becker fullname: Becker, Jürgen C. organization: Institute for Translational Dermato-Oncology, German Cancer Research Center, Medical University of Essen, Germany – sequence: 9 givenname: Iris surname: Zalaudek fullname: Zalaudek, Iris organization: Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria – sequence: 10 givenname: Philippe surname: Saiag fullname: Saiag, Philippe organization: University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France – sequence: 11 givenname: Mark R. surname: Middleton fullname: Middleton, Mark R. organization: Department of Oncology, Oxford National Institute for Health Research Biomedical Research Centre, United Kingdom – sequence: 12 givenname: Lars surname: Bastholt fullname: Bastholt, Lars organization: Department of Oncology, Odense University Hospital, Denmark – sequence: 13 givenname: Alessandro surname: Testori fullname: Testori, Alessandro organization: Istituto Europeo di Oncologia, Divisione Dermato-Oncologica, Milan, Italy – sequence: 14 givenname: Jean-Jacques surname: Grob fullname: Grob, Jean-Jacques organization: University Department of Dermatology, Marseille, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26219687$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUsFu1TAQtFARfS38AAfkI5cE2y-x4wohodIWpEocgLPl2JviNLFfbedJPfDvOHrtpRLltJZ2Zrw7syfoyAcPCL2lpKaE8g9jDaPRNSO0rQmvKSUv0IZ2Qlaka9kR2hDZyqojjTxGJymNhBDRNeQVOmacUck7sUF_vjh940NyCWtvcY6g8ww-4zBg5_c6uT3gdLfoOSwJG5gmbHQ0zodZr5j8u7RvnT_DF0sMO9Aem-AT-LSkqtcJbJHJEK1Lxu0m53W8xzeLs1De8Bq9HPSU4M1DPUW_Li9-nn-trr9ffTv_fF2ZVrBcyU42egDGhy23TT9IKhtqBCei7YgVkvOei36wvLGsabeD1hzsYAyT2x6YMNtT9P6gu4vhboGU1VzmKctoD2UvRQXhreANpQX67gG69DNYtYtuLjOrR8sKoDsATAwpRRiUcVlnF3yO2k2KErWmo0a1pqPWdBThqqRTqOwJ9VH9WdLHAwmKQXsHURUnwRuwLoLJygb3PP3TE7opzjujp1u4hzSGJfpivaIqMUXUj_Vm1pOhLSGctW0ROPu3wP9-_wsstdNU |
| CitedBy_id | crossref_primary_10_1111_jdv_16001 crossref_primary_10_1016_j_jaad_2017_08_058 crossref_primary_10_18621_eurj_538156 crossref_primary_10_1002_jum_16255 crossref_primary_10_1111_jdv_15950 crossref_primary_10_1016_j_bjps_2021_08_041 crossref_primary_10_1111_jdv_16007 crossref_primary_10_1053_j_seminoncol_2019_04_002 crossref_primary_10_1016_j_ctarc_2021_100413 crossref_primary_10_5812_ijcm_60846 crossref_primary_10_1097_CCO_0000000000000566 crossref_primary_10_7759_cureus_86907 crossref_primary_10_1111_ddg_14048_g crossref_primary_10_1016_j_oraloncology_2019_104459 crossref_primary_10_1007_s40257_016_0207_3 crossref_primary_10_1007_s40265_020_01302_2 crossref_primary_10_1111_bjd_14642 crossref_primary_10_1111_ced_13570 crossref_primary_10_1111_ddg_14048 crossref_primary_10_2217_imt_2021_0306 crossref_primary_10_1097_CM9_0000000000000070 crossref_primary_10_1007_s00105_020_04620_4 crossref_primary_10_1080_14737140_2022_2125382 crossref_primary_10_3390_cancers11091216 crossref_primary_10_2340_actadv_v105_40727 crossref_primary_10_3166_onco_2018_0009 crossref_primary_10_1055_a_1949_3773 crossref_primary_10_1016_j_ejso_2018_05_031 crossref_primary_10_3390_life15081257 crossref_primary_10_1111_dth_14035 crossref_primary_10_1016_j_adengl_2018_03_018 crossref_primary_10_1016_j_jcms_2019_11_022 crossref_primary_10_3390_cosmetics10060165 crossref_primary_10_1002_jso_24870 crossref_primary_10_3390_cancers16233925 crossref_primary_10_1007_s11864_019_0629_2 crossref_primary_10_1080_14737140_2021_1876567 crossref_primary_10_1117_1_JBO_30_3_035001 crossref_primary_10_1111_vde_13282 crossref_primary_10_1172_JCI150750 crossref_primary_10_1007_s11517_020_02241_6 crossref_primary_10_1007_s12094_018_1891_7 crossref_primary_10_1093_ced_llae160 crossref_primary_10_1186_s40425_018_0444_5 crossref_primary_10_1016_j_jaad_2016_09_024 crossref_primary_10_1016_j_abd_2023_05_006 crossref_primary_10_3389_fmed_2024_1380405 crossref_primary_10_1111_dth_13156 crossref_primary_10_1186_s12957_017_1191_7 crossref_primary_10_3390_healthcare12090921 crossref_primary_10_3390_genes11070751 crossref_primary_10_1016_j_ad_2018_03_007 crossref_primary_10_1002_hed_24580 crossref_primary_10_3390_pharmaceutics13101562 crossref_primary_10_3389_fonc_2023_1141820 crossref_primary_10_1007_s00403_021_02244_9 crossref_primary_10_1016_j_jid_2016_06_630 crossref_primary_10_1111_bjd_15274 crossref_primary_10_1016_j_ajoc_2024_102089 crossref_primary_10_1007_s00411_023_01020_9 crossref_primary_10_1097_DSS_0000000000003462 crossref_primary_10_1001_jamaoto_2025_2110 crossref_primary_10_1111_jdv_16210 crossref_primary_10_1002_jbio_201800468 crossref_primary_10_1007_s40487_024_00304_4 crossref_primary_10_3390_molecules23112987 crossref_primary_10_1016_j_ymthe_2017_12_005 crossref_primary_10_1007_s11864_016_0435_z crossref_primary_10_1186_s12874_023_02109_x crossref_primary_10_1093_bjd_ljaf205 crossref_primary_10_1002_ccr3_3823 crossref_primary_10_1016_j_bjps_2019_06_034 crossref_primary_10_3390_molecules26113403 crossref_primary_10_1155_jskc_1823281 crossref_primary_10_1007_s13671_019_0261_1 crossref_primary_10_2340_actadv_v104_13213 crossref_primary_10_1007_s12254_019_00554_3 crossref_primary_10_1111_jdv_18101 crossref_primary_10_3390_cancers16020471 crossref_primary_10_1038_s41698_022_00261_z crossref_primary_10_3390_cancers14122876 crossref_primary_10_3390_electronics10030243 crossref_primary_10_1111_dth_15715 crossref_primary_10_1111_cup_14331 crossref_primary_10_3389_fonc_2023_1117804 crossref_primary_10_1111_jdv_16849 crossref_primary_10_3390_cancers16081469 crossref_primary_10_1016_j_bjps_2017_03_005 crossref_primary_10_1016_j_compbiomed_2022_105505 crossref_primary_10_1055_a_1666_3585 crossref_primary_10_3389_fonc_2021_650974 crossref_primary_10_1111_bjd_19697 crossref_primary_10_1111_iwj_13354 crossref_primary_10_1055_a_2171_4570 crossref_primary_10_1111_dth_13547 crossref_primary_10_2217_imt_2020_0042 crossref_primary_10_1016_j_ijrobp_2018_12_009 crossref_primary_10_1136_bcr_2019_233305 crossref_primary_10_1136_jitc_2021_002757 crossref_primary_10_1016_j_ejca_2023_113252 crossref_primary_10_4103_ijd_ijd_1147_20 crossref_primary_10_1002_hed_26237 crossref_primary_10_1007_s00106_025_01564_w crossref_primary_10_1016_j_neo_2022_100810 crossref_primary_10_3390_biomedicines9020171 crossref_primary_10_3390_ma9060464 crossref_primary_10_1002_jso_24675 crossref_primary_10_1111_ddg_14531 crossref_primary_10_1111_ans_18694 crossref_primary_10_3390_cells9112375 crossref_primary_10_1111_cup_12728 crossref_primary_10_1371_journal_pone_0184034 crossref_primary_10_1111_ddg_13477_g crossref_primary_10_3390_cancers12020489 crossref_primary_10_1016_j_jid_2020_01_035 crossref_primary_10_1177_11206721211035629 crossref_primary_10_7759_cureus_78020 crossref_primary_10_1111_jdv_16268 crossref_primary_10_3390_cancers16244279 crossref_primary_10_1111_exd_14782 crossref_primary_10_1111_jdv_14887 crossref_primary_10_3389_fsurg_2022_964210 crossref_primary_10_1016_j_jaad_2018_08_032 crossref_primary_10_1007_s00761_016_0065_x crossref_primary_10_1111_cup_13709 crossref_primary_10_1155_2018_8739473 crossref_primary_10_3390_cancers15133291 crossref_primary_10_1016_j_jaad_2022_01_053 crossref_primary_10_1016_j_jaad_2020_12_020 crossref_primary_10_1111_ddg_14531_g crossref_primary_10_1007_s11864_024_01197_1 crossref_primary_10_1007_s10544_025_00735_4 crossref_primary_10_1016_j_ejcskn_2023_100004 crossref_primary_10_1111_jdv_15845 crossref_primary_10_1016_j_otc_2020_11_007 crossref_primary_10_1080_10520295_2024_2302016 crossref_primary_10_1080_2000656X_2016_1270215 crossref_primary_10_1111_jdv_15846 crossref_primary_10_1111_cup_13392 crossref_primary_10_1111_ddg_14072 crossref_primary_10_3390_cancers16101800 crossref_primary_10_1097_CAD_0000000000000551 crossref_primary_10_1111_ddg_13546 crossref_primary_10_1016_j_lpm_2017_09_016 crossref_primary_10_1001_jamadermatol_2025_1614 crossref_primary_10_1016_j_annder_2017_05_002 crossref_primary_10_3389_fonc_2021_638395 crossref_primary_10_3390_ani13081327 crossref_primary_10_1155_2024_3859066 crossref_primary_10_1111_cup_12869 crossref_primary_10_1038_s41418_021_00875_z crossref_primary_10_1158_1078_0432_CCR_20_0232 crossref_primary_10_12968_hmed_2019_80_6_331 crossref_primary_10_3389_fonc_2023_1111907 crossref_primary_10_1038_s41598_023_38890_4 crossref_primary_10_1016_j_bjoms_2021_01_003 crossref_primary_10_1016_j_envres_2024_118117 crossref_primary_10_1111_aos_15819 crossref_primary_10_1158_0008_5472_CAN_18_1495 crossref_primary_10_7759_cureus_37694 crossref_primary_10_2217_fon_2019_0762 crossref_primary_10_1002_adfm_201806883 crossref_primary_10_1016_j_omtn_2020_04_014 crossref_primary_10_1007_s00105_017_3951_2 crossref_primary_10_1016_j_jaad_2020_03_088 crossref_primary_10_1111_ddg_13477 crossref_primary_10_1111_bjd_19017 crossref_primary_10_1016_j_ad_2019_06_005 crossref_primary_10_1016_j_jval_2020_09_014 crossref_primary_10_1016_j_prmcm_2024_100378 crossref_primary_10_1159_000501250 crossref_primary_10_1016_j_oraloncology_2022_105847 crossref_primary_10_1097_DSS_0000000000003085 crossref_primary_10_1111_bjd_14923 crossref_primary_10_1111_jdv_16098 crossref_primary_10_1111_bjd_15906 crossref_primary_10_1111_cup_12766 crossref_primary_10_12659_AJCR_902828 crossref_primary_10_1002_lary_29842 crossref_primary_10_3892_ol_2019_10308 crossref_primary_10_2147_CCID_S381471 crossref_primary_10_1007_s00405_016_4243_7 crossref_primary_10_3389_fphar_2017_00698 crossref_primary_10_1016_j_bjps_2023_06_030 crossref_primary_10_3390_ijms21155394 crossref_primary_10_2217_fon_2023_0389 crossref_primary_10_1007_s11864_025_01335_3 crossref_primary_10_12688_f1000research_19149_1 crossref_primary_10_1148_radiol_2020192190 crossref_primary_10_12688_f1000research_19149_2 crossref_primary_10_1007_s00520_021_06034_x crossref_primary_10_1016_j_cll_2017_06_003 crossref_primary_10_1016_j_survophthal_2020_10_005 crossref_primary_10_1111_bjd_19485 crossref_primary_10_1016_j_jcms_2021_02_009 crossref_primary_10_1016_j_jpha_2023_11_002 crossref_primary_10_1684_ejd_2020_3710 crossref_primary_10_1016_j_jdermsci_2023_06_001 crossref_primary_10_1007_s11654_019_0144_8 crossref_primary_10_1097_DSS_0000000000004037 crossref_primary_10_1111_1346_8138_14342 crossref_primary_10_1016_j_ejca_2019_05_010 crossref_primary_10_1111_php_70008 crossref_primary_10_1056_NEJMoa1805131 crossref_primary_10_17650_2222_1468_2023_13_4_116_123 crossref_primary_10_1080_2000656X_2022_2060993 crossref_primary_10_3390_jcm12123929 crossref_primary_10_1016_j_jcms_2017_05_015 crossref_primary_10_1186_s13244_022_01205_8 crossref_primary_10_1111_ddg_14072_g crossref_primary_10_1016_j_ejca_2020_01_008 crossref_primary_10_1002_lary_27881 crossref_primary_10_1016_j_jdermsci_2017_02_281 crossref_primary_10_1371_journal_pone_0144028 crossref_primary_10_1016_j_ejca_2020_01_007 crossref_primary_10_3390_cancers16132394 crossref_primary_10_3390_biom13071067 crossref_primary_10_1002_cam4_3146 crossref_primary_10_1016_j_adengl_2019_06_007 crossref_primary_10_1155_2022_9529681 crossref_primary_10_18203_2349_3933_ijam20252534 crossref_primary_10_1002_hed_24512 crossref_primary_10_26416_Inf_56_4_2018_2187 crossref_primary_10_1002_jso_24134 crossref_primary_10_1016_j_pdpdt_2021_102545 crossref_primary_10_3390_ijms19061791 crossref_primary_10_1159_000447508 crossref_primary_10_3390_jcm13061581 crossref_primary_10_1016_j_anndiagpath_2019_06_013 crossref_primary_10_1684_ejd_2018_3403 crossref_primary_10_1186_s40463_019_0374_3 crossref_primary_10_1002_anbr_202200143 crossref_primary_10_1111_cas_16392 crossref_primary_10_7759_cureus_10997 crossref_primary_10_1684_ejd_2017_3209 crossref_primary_10_3390_ijms20235946 crossref_primary_10_7759_cureus_65447 crossref_primary_10_1016_j_jaad_2018_02_075 crossref_primary_10_1097_DSS_0000000000001828 crossref_primary_10_1080_0284186X_2018_1454602 crossref_primary_10_3390_cancers15133348 crossref_primary_10_3892_ol_2021_12867 crossref_primary_10_1038_s41598_017_12836_z crossref_primary_10_3892_ijo_2019_4727 crossref_primary_10_3389_fonc_2024_1525926 crossref_primary_10_1016_j_jid_2018_04_009 crossref_primary_10_1097_SCS_0000000000005895 crossref_primary_10_1007_s00403_024_03184_w crossref_primary_10_1097_DSS_0000000000003324 crossref_primary_10_1111_ced_14066 crossref_primary_10_3389_fonc_2020_00564 crossref_primary_10_1097_CAD_0000000000000946 crossref_primary_10_1097_MOO_0000000000000960 crossref_primary_10_1186_s12885_018_4218_8 crossref_primary_10_1038_s41467_024_53908_9 crossref_primary_10_1080_14740338_2022_1993819 crossref_primary_10_1016_j_actpha_2018_10_005 crossref_primary_10_1055_a_1895_0721 crossref_primary_10_1007_s13671_025_00475_x crossref_primary_10_2217_fon_2020_0823 crossref_primary_10_3892_etm_2024_12619 crossref_primary_10_1080_09546634_2019_1592099 crossref_primary_10_3390_ijms21249536 crossref_primary_10_1038_s41389_019_0161_z crossref_primary_10_1038_s41598_020_59660_6 crossref_primary_10_1111_exd_13979 crossref_primary_10_3389_fonc_2018_00079 crossref_primary_10_3390_biomedicines11071818 crossref_primary_10_1111_1754_9485_12842 crossref_primary_10_1007_s00262_017_2015_x crossref_primary_10_1111_ijd_15755 crossref_primary_10_4103_jcrt_JCRT_1032_17 crossref_primary_10_1155_crom_7038584 crossref_primary_10_1055_a_1396_8087 crossref_primary_10_1002_jbio_202500146 crossref_primary_10_1038_s41388_019_0773_y crossref_primary_10_3389_fonc_2021_689789 crossref_primary_10_1016_j_ccr_2022_214757 crossref_primary_10_3390_microorganisms12020293 crossref_primary_10_3390_cancers14030550 crossref_primary_10_1016_j_ejca_2018_01_075 crossref_primary_10_1371_journal_pone_0204330 crossref_primary_10_1097_PGP_0000000000000794 crossref_primary_10_1007_s00105_016_3875_2 crossref_primary_10_1097_DSS_0000000000003304 crossref_primary_10_1111_ddg_13546_g crossref_primary_10_3390_ijms26168109 crossref_primary_10_1007_s00761_017_0185_y crossref_primary_10_1158_1078_0432_CCR_21_0585 crossref_primary_10_1016_j_jcms_2018_08_013 crossref_primary_10_1007_s00403_020_02114_w crossref_primary_10_1186_s13256_017_1281_8 crossref_primary_10_1177_00031348231175107 crossref_primary_10_1111_bjd_17792 crossref_primary_10_1097_CCO_0000000000000359 crossref_primary_10_1016_j_jaad_2016_06_010 crossref_primary_10_1136_jitc_2020_000775 crossref_primary_10_1515_sjdv_2017_0019 crossref_primary_10_3389_fmed_2019_00207 crossref_primary_10_1016_j_ejca_2018_04_004 crossref_primary_10_1016_j_jaad_2018_06_060 crossref_primary_10_1097_MD_0000000000022257 crossref_primary_10_1016_j_pathol_2023_07_003 crossref_primary_10_7759_cureus_86267 crossref_primary_10_1001_jamadermatol_2017_6428 crossref_primary_10_21676_2389783X_3217 crossref_primary_10_1016_j_coms_2017_04_001 crossref_primary_10_1016_j_pharmthera_2018_09_007 crossref_primary_10_1016_j_jconrel_2018_05_038 crossref_primary_10_1111_dth_13250 crossref_primary_10_1016_j_jid_2016_05_110 crossref_primary_10_1111_1346_8138_15889 crossref_primary_10_1155_2024_9960948 |
| Cites_doi | 10.1067/S0190-9622(03)01587-1 10.1001/jamadermatol.2013.6675 10.1111/bjd.12519 10.1001/archdermatol.2010.19 10.1097/DAD.0000000000000031 10.1016/j.bjps.2012.04.031 10.1111/j.1365-2133.2012.10830.x 10.1158/0008-5472.CAN-09-2976 10.1002/ijc.2910530410 10.1016/j.jaad.2012.11.037 10.1111/j.1468-3083.2004.00829.x 10.1136/bmj.1.6003.188 10.1056/NEJMoa1204166 10.1001/jama.1989.03430150065027 10.1038/sj.bjc.6601894 10.1002/cncr.21898 10.1016/j.jaad.2012.01.010 10.1200/JCO.1990.8.2.342 10.1001/jamadermatol.2013.2139 10.1200/JCO.2005.02.4646 10.1001/archderm.1997.03890420073008 10.1038/jid.2009.426 10.1016/S1470-2045(08)70178-5 10.1002/hed.20048 10.1111/j.1529-8019.2010.01370.x 10.1038/jid.2012.403 10.1016/j.ijrobp.2012.09.030 10.1097/00000478-199205000-00001 10.1111/j.1440-1673.2008.01956.x 10.1016/S0190-9622(80)80007-7 10.1002/1097-0142(19910415)67:8<2030::AID-CNCR2820670803>3.0.CO;2-K 10.1200/JCO.2002.20.2.364 10.1046/j.0007-0963.2001.04615.x 10.1111/bjd.12420 10.1016/0190-9622(95)90239-2 10.1136/bmj.f6153 10.1016/S0190-9622(94)70073-7 10.1158/0008-5472.CAN-09-1186 10.1054/ijom.2002.0326 10.1097/00000421-200112000-00019 10.1200/JCO.2010.34.1735 10.1016/j.coms.2012.11.008 10.1093/jnci/84.4.235 10.1684/ejd.2013.2106 10.1016/j.ejso.2006.10.017 10.1002/ijc.25411 10.1016/j.jaad.2013.02.008 10.1158/1078-0432.CCR-11-1951 10.1016/j.ejca.2012.01.003 10.1002/(SICI)1097-0142(19970301)79:5<915::AID-CNCR7>3.0.CO;2-A 10.1200/JCO.2006.05.9873 10.1200/jco.2007.25.18_suppl.16519 10.7150/jca.3491 10.1016/0002-9610(84)90385-4 10.1001/jamadermatol.2013.2456 10.1111/j.1468-3083.2011.04296.x 10.1001/jamadermatol.2014.762 10.1200/jco.2006.24.18_suppl.5531 10.1001/jamadermatol.2013.746 10.1111/j.1600-0560.1992.tb01364.x 10.1093/carcin/bgi123 10.1056/NEJMra022137 10.1038/jid.2009.141 10.1093/annonc/mdt015 10.1172/JCI57415 10.1002/1097-0142(19800515)45:10<2687::AID-CNCR2820451034>3.0.CO;2-R 10.1016/0190-9622(92)70178-I 10.1038/ncponc0883 10.1111/j.1365-2133.2012.11081.x 10.1046/j.1523-1747.2001.01224.x 10.1016/S0190-9622(98)70596-1 10.1200/JCO.2006.09.2759 10.1111/j.1365-2133.2011.10238.x 10.1016/j.jaad.2010.11.063 10.1097/00000421-200004000-00015 10.1038/bjc.1996.303 10.1097/EDE.0b013e3181567ebe 10.1067/mjd.2002.125579 10.1002/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y 10.1016/j.jaad.2005.10.049 10.1016/j.jaad.2006.12.017 10.1016/S0140-6736(88)91658-3 10.5694/j.1326-5377.2006.tb00086.x 10.1002/jso.23155 10.1111/1346-8138.12424 10.1111/j.1365-2133.2003.05554.x 10.1002/cncr.26374 10.1002/cncr.22509 10.1001/archderm.139.3.301 10.1111/j.1365-2133.2011.10524.x 10.1111/j.1468-3083.2011.04432.x 10.1001/jama.294.6.681 10.1016/S1470-2045(12)70413-8 10.1001/archsurg.134.3.303 |
| ContentType | Journal Article |
| Copyright | 2015 Elsevier Ltd Elsevier Ltd Copyright © 2015 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2015 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2015 Elsevier Ltd. All rights reserved. |
| CorporateAuthor | European Association of Dermato-Oncology (EADO) European Dermatology Forum (EDF) European Organization for Research and Treatment of Cancer (EORTC) |
| CorporateAuthor_xml | – name: European Organization for Research and Treatment of Cancer (EORTC) – name: European Dermatology Forum (EDF) – name: European Association of Dermato-Oncology (EADO) |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ejca.2015.06.110 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0852 |
| EndPage | 2007 |
| ExternalDocumentID | 26219687 10_1016_j_ejca_2015_06_110 S0959804915006255 1_s2_0_S0959804915006255 |
| Genre | Journal Article Practice Guideline Review |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU DOVZS LCYCR ZA5 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c572t-9894afe26f36d4bf91941c7607580d7966b67bfd64d2453faa6edfcc293be27c3 |
| ISICitedReferencesCount | 369 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000360081300017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0959-8049 1879-0852 |
| IngestDate | Sat Sep 27 20:38:02 EDT 2025 Wed Feb 19 01:57:57 EST 2025 Tue Nov 18 22:20:24 EST 2025 Sat Nov 29 02:23:55 EST 2025 Fri Feb 23 02:20:28 EST 2024 Sun Feb 23 10:18:56 EST 2025 Tue Oct 14 19:35:10 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Keywords | Pathology Surgical excision Follow up Cutaneous squamous cell carcinoma Prognosis Systemic treatment Diagnosis Management Radiation therapy |
| Language | English |
| License | Copyright © 2015 Elsevier Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c572t-9894afe26f36d4bf91941c7607580d7966b67bfd64d2453faa6edfcc293be27c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Instructional Material/Guideline-3 ObjectType-Review-4 content type line 23 |
| OpenAccessLink | http://www.ejcancer.com/article/S0959804915006255/pdf |
| PMID | 26219687 |
| PQID | 1706576411 |
| PQPubID | 23479 |
| PageCount | 19 |
| ParticipantIDs | proquest_miscellaneous_1706576411 pubmed_primary_26219687 crossref_citationtrail_10_1016_j_ejca_2015_06_110 crossref_primary_10_1016_j_ejca_2015_06_110 elsevier_sciencedirect_doi_10_1016_j_ejca_2015_06_110 elsevier_clinicalkeyesjournals_1_s2_0_S0959804915006255 elsevier_clinicalkey_doi_10_1016_j_ejca_2015_06_110 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-09-01 |
| PublicationDateYYYYMMDD | 2015-09-01 |
| PublicationDate_xml | – month: 09 year: 2015 text: 2015-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | European journal of cancer (1990) |
| PublicationTitleAlternate | Eur J Cancer |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Jambusaria-Pahlajani, Kanetsky, Karia (b0220) 2013; 149 Werner, Sammain, Erdmann, Hartmann, Stockfleth, Nast (b0165) 2013; 169 Annest, VanBeek, Arpey, Whitaker (b0295) 2007; 56 Brantsch, Meisner, Schönfisch (b0235) 2008; 9 Veness, Palme, Morgan (b0370) 2006; 106 Kumar, Soares, Balducci (b0420) 2007; 25 Boukamp (b0145) 2005; 26 Katalinic, Kunze, Schäfer (b0075) 2003; 149 Veness (b0325) 2008; 52 Anforth, Fernandez-Peñas, Long (b0180) 2013; 14 No authors listed (b0495) 1976; 1 Stockfleth (b0465) 2012; 11 Goepfert, Dichtel, Medina, Lindberg, Luna (b0250) 1984; 148 Bajdik, Gallagher, Astrakianakis (b0100) 1996; 73 Braathen, Morton, Basset-Seguin, Bissonnette, Gerritsen, Gilaberte (b0470) 2012; 26 Karagas, Nelson, Zens (b0105) 2007; 18 . Han, Ratner (b0375) 2007; 109 Aoyagi, Hata, Homma, Shimizu (b0315) 2014; 41 Renzi, Caggiati, Mannooranparampil (b0350) 2007; 33 Bonerandi, Beauvillain, Caquant (b0010) 2011; 25 Lippman, Parkinson, Itri (b0435) 1992; 84 Sadek, Azli, Wendling (b0395) 1990; 66 Lewis, Glisson, Feng (b0455) 2012; 18 Glisson, Kim, Kies (b0500) 2006; 24 Heath, Deep, Nabell (b0505) 2013; 85 Boussemart, Routier, Mateus, Opletalova, Sebille, Kamsu-Kom (b0135) 2013; 24 Xiang, Lucas, Hales, Neale (b0055) 2014; 150 Zhao, Li, Marshall (b0150) 2009; 69 Harwood, Proby, McGregor, Sheaff, Leigh, Cerio (b0130) 2006; 54 Zwald, Brown (b0265) 2011; 65 Rogers, Weinstock, Harris (b0025) 2010; 146 Maubec, Petrow, Scheer-Senyarich (b0445) 2011; 29 de Vries, Trakatelli, Kalabalikis (b0090) 2012; 167 Hofbauer, Anliker, Arnold (b0475) 2009; 139 Birch-Johansen, Jensen, Mortensen, Olesen, Kjær (b0065) 2010; 127 DE Bamford (b0155) 2004; 91 Ross, Schmults (b0345) 2006; 32 Olieman, Liénard, Eggermont (b0425) 1999; 134 Lansbury, Bath-Hextall, Perkins, Stanton, Leonardi-Bee (b0320) 2013; 347 Neville, Welch, Leffell (b0335) 2007; 4 Lecerf, Richert, Theunis, André (b0300) 2013; 69 Edge, Byrd, Compton (b0210) 2009 Evans, Smith (b0185) 1980; 45 Goette, Odom (b0290) 1980; 2 Cartei, Cartei, Interlandi (b0400) 2000; 23 Berg, Otley (b0125) 2002; 47 Breuninger, Eigentler, Bootz (b0005) 2012; 10 Behshad, Garcia-Zuazaga, Bordeaux (b0390) 2011; 165 Kadakia, Barton, Loprinzi, Sloan, Otley, Diekmann (b0285) 2012; 118 Savage, Maize (b0175) 2013; 36 Metchnikoff, Mully, Singer, Golden, Arron (b0215) 2012; 67 Ratushny, Gober, Hick, Ridky, Seykora (b0140) 2012; 122 Christenson, Borrowman, Vachon (b0085) 2005; 294 Breuninger, Schaumburg-Lever, Holzschuh, Horny (b0195) 1997; 79 Martinez, Otley, Stasko, Euvrard, Brown, Schanbacher (b0275) 2003; 139 Maubec, Duvillard, Velasco (b0440) 2005; 25 Geohas, Roholt, Robinson (b0365) 1994; 30 Wong, Tan, Goh (b0110) 1998; 38 Box, Duffy, Irving (b0120) 2001; 116 Brodland, Zitelli (b0305) 1992; 27 Carter, Johnson, Chua, Karia, Schmults (b0255) 2013; 149 Audet, Palme, Gullane (b0360) 2004; 26 Euvrard, Kanitakis, Claudy (b0260) 2003; 348 Glass (b0030) 1989; 262 Bovill, Banwell (b0245) 2012; 65 Burtness, Goldwasser, Flood (b0450) 2005; 23 Marks, Rennie, Selwood (b0160) 1988; 1 Testori, Tosti, Martinoli, Spadola, Cataldo, Verrecchia (b0385) 2010; 23 Nijsten, Stern (b0480) 2003; 49 Kalapurakal, Malone, Robbins (b0510) 2012; 3 Shin, Glisson, Khuri (b0430) 2002; 20 Schmults, Karia, Carter, Han, Qureshi (b0230) 2013; 149 Schmitt, Brewer, Bordeaux, Baum (b0355) 2013; 150 Staples, Elwood, Burton, Williams, Marks, Giles (b0045) 2006; 184 Marks, Staples, Giles (b0115) 1993; 53 Sobin, Gospodarowicz, Wittekind (b0205) 2009 Guthrie, Porubsky, Luxenberg (b0405) 1990; 8 Khansur, Kennedy (b0410) 1991; 67 Nappi, Wick, Pettinato, Ghiselli, Swanson (b0200) 1992; 16 Hollestein, de Vries, Nijsten (b0080) 2012; 48 Read (b0515) 2007; 25 Euvrard, Kanitakis, Pouteil-Noble (b0270) 1995; 33 Chren, Linos, Torres, Stuart, Parvataneni, Boscardin (b0310) 2013; 133 Cuperus, Leguit, Albregts, Toonstra (b0340) 2013; 23 Brewster, Lee, Clayman (b0380) 2007; 25 Benasso, Merlano, Sanquieti (b0415) 2001; 24 Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Version I.2013. Available at Brougham, Dennett, Cameron, Tan (b0240) 2012; 106 Hussain, Sundquist, Hemminki (b0070) 2010; 130 Gray, Su, Clay, Harmsen, Roenigk (b0035) 1997; 133 Gordon, Scuffham, van der Pols, McBride, Williams, Green (b0460) 2009; 129 Motley, Kersey, Lawrence (b0015) 2002; 146 Karia, Han, Schmults (b0050) 2013; 68 Smith, Skelton, Morgan (b0190) 1992; 19 Revenga Arranz, Paricio Rubio, Mar Vazquez Salvado (b0095) 2004; 18 Carsin, Sharp, Comber (b0060) 2011; 164 Stockfleth, Kerl (b0280) 2006; 16 Plasmeijer, Neale, de Koning (b0170) 2009; 69 Jank, Robatscher, Emshoff, Strobl, Gojer, Norer (b0225) 2003; 32 Euvrard, Morelon, Rostaing, Goffin, Brocard, Tromme (b0490) 2012; 367 Sciubba, Helman (b0330) 2013; 25 Lomas, Leonardi-Bee, Bath-Hextall (b0040) 2012; 166 Anforth, Blumetti, Clements, Kefford, Long, Fernandez-Peñas (b0485) 2013; 169 Breuninger (10.1016/j.ejca.2015.06.110_b0005) 2012; 10 Hofbauer (10.1016/j.ejca.2015.06.110_b0475) 2009; 139 Marks (10.1016/j.ejca.2015.06.110_b0115) 1993; 53 Bovill (10.1016/j.ejca.2015.06.110_b0245) 2012; 65 Annest (10.1016/j.ejca.2015.06.110_b0295) 2007; 56 Kadakia (10.1016/j.ejca.2015.06.110_b0285) 2012; 118 Anforth (10.1016/j.ejca.2015.06.110_b0180) 2013; 14 Goepfert (10.1016/j.ejca.2015.06.110_b0250) 1984; 148 Hollestein (10.1016/j.ejca.2015.06.110_b0080) 2012; 48 Plasmeijer (10.1016/j.ejca.2015.06.110_b0170) 2009; 69 Sciubba (10.1016/j.ejca.2015.06.110_b0330) 2013; 25 Boukamp (10.1016/j.ejca.2015.06.110_b0145) 2005; 26 Stockfleth (10.1016/j.ejca.2015.06.110_b0465) 2012; 11 Maubec (10.1016/j.ejca.2015.06.110_b0445) 2011; 29 Bonerandi (10.1016/j.ejca.2015.06.110_b0010) 2011; 25 Berg (10.1016/j.ejca.2015.06.110_b0125) 2002; 47 Lippman (10.1016/j.ejca.2015.06.110_b0435) 1992; 84 Testori (10.1016/j.ejca.2015.06.110_b0385) 2010; 23 Sadek (10.1016/j.ejca.2015.06.110_b0395) 1990; 66 Khansur (10.1016/j.ejca.2015.06.110_b0410) 1991; 67 Box (10.1016/j.ejca.2015.06.110_b0120) 2001; 116 Zwald (10.1016/j.ejca.2015.06.110_b0265) 2011; 65 Martinez (10.1016/j.ejca.2015.06.110_b0275) 2003; 139 Gray (10.1016/j.ejca.2015.06.110_b0035) 1997; 133 Anforth (10.1016/j.ejca.2015.06.110_b0485) 2013; 169 DE Bamford (10.1016/j.ejca.2015.06.110_b0155) 2004; 91 Euvrard (10.1016/j.ejca.2015.06.110_b0490) 2012; 367 Rogers (10.1016/j.ejca.2015.06.110_b0025) 2010; 146 Brewster (10.1016/j.ejca.2015.06.110_b0380) 2007; 25 Maubec (10.1016/j.ejca.2015.06.110_b0440) 2005; 25 Lomas (10.1016/j.ejca.2015.06.110_b0040) 2012; 166 Olieman (10.1016/j.ejca.2015.06.110_b0425) 1999; 134 Cuperus (10.1016/j.ejca.2015.06.110_b0340) 2013; 23 Veness (10.1016/j.ejca.2015.06.110_b0325) 2008; 52 Wong (10.1016/j.ejca.2015.06.110_b0110) 1998; 38 Edge (10.1016/j.ejca.2015.06.110_b0210) 2009 Smith (10.1016/j.ejca.2015.06.110_b0190) 1992; 19 Brantsch (10.1016/j.ejca.2015.06.110_b0235) 2008; 9 Stockfleth (10.1016/j.ejca.2015.06.110_b0280) 2006; 16 Braathen (10.1016/j.ejca.2015.06.110_b0470) 2012; 26 Harwood (10.1016/j.ejca.2015.06.110_b0130) 2006; 54 Katalinic (10.1016/j.ejca.2015.06.110_b0075) 2003; 149 Neville (10.1016/j.ejca.2015.06.110_b0335) 2007; 4 Shin (10.1016/j.ejca.2015.06.110_b0430) 2002; 20 Kalapurakal (10.1016/j.ejca.2015.06.110_b0510) 2012; 3 Karia (10.1016/j.ejca.2015.06.110_b0050) 2013; 68 Christenson (10.1016/j.ejca.2015.06.110_b0085) 2005; 294 Han (10.1016/j.ejca.2015.06.110_b0375) 2007; 109 Aoyagi (10.1016/j.ejca.2015.06.110_b0315) 2014; 41 Geohas (10.1016/j.ejca.2015.06.110_b0365) 1994; 30 Read (10.1016/j.ejca.2015.06.110_b0515) 2007; 25 Euvrard (10.1016/j.ejca.2015.06.110_b0260) 2003; 348 Cartei (10.1016/j.ejca.2015.06.110_b0400) 2000; 23 Jambusaria-Pahlajani (10.1016/j.ejca.2015.06.110_b0220) 2013; 149 Werner (10.1016/j.ejca.2015.06.110_b0165) 2013; 169 Carter (10.1016/j.ejca.2015.06.110_b0255) 2013; 149 Marks (10.1016/j.ejca.2015.06.110_b0160) 1988; 1 Lecerf (10.1016/j.ejca.2015.06.110_b0300) 2013; 69 Glisson (10.1016/j.ejca.2015.06.110_b0500) 2006; 24 Chren (10.1016/j.ejca.2015.06.110_b0310) 2013; 133 Sobin (10.1016/j.ejca.2015.06.110_b0205) 2009 Breuninger (10.1016/j.ejca.2015.06.110_b0195) 1997; 79 Behshad (10.1016/j.ejca.2015.06.110_b0390) 2011; 165 Ross (10.1016/j.ejca.2015.06.110_b0345) 2006; 32 Gordon (10.1016/j.ejca.2015.06.110_b0460) 2009; 129 Carsin (10.1016/j.ejca.2015.06.110_b0060) 2011; 164 Motley (10.1016/j.ejca.2015.06.110_b0015) 2002; 146 Revenga Arranz (10.1016/j.ejca.2015.06.110_b0095) 2004; 18 Schmitt (10.1016/j.ejca.2015.06.110_b0355) 2013; 150 Jank (10.1016/j.ejca.2015.06.110_b0225) 2003; 32 Benasso (10.1016/j.ejca.2015.06.110_b0415) 2001; 24 Burtness (10.1016/j.ejca.2015.06.110_b0450) 2005; 23 Glass (10.1016/j.ejca.2015.06.110_b0030) 1989; 262 Karagas (10.1016/j.ejca.2015.06.110_b0105) 2007; 18 Savage (10.1016/j.ejca.2015.06.110_b0175) 2013; 36 Ratushny (10.1016/j.ejca.2015.06.110_b0140) 2012; 122 Schmults (10.1016/j.ejca.2015.06.110_b0230) 2013; 149 Lewis (10.1016/j.ejca.2015.06.110_b0455) 2012; 18 de Vries (10.1016/j.ejca.2015.06.110_b0090) 2012; 167 Bajdik (10.1016/j.ejca.2015.06.110_b0100) 1996; 73 Kumar (10.1016/j.ejca.2015.06.110_b0420) 2007; 25 Guthrie (10.1016/j.ejca.2015.06.110_b0405) 1990; 8 Staples (10.1016/j.ejca.2015.06.110_b0045) 2006; 184 Hussain (10.1016/j.ejca.2015.06.110_b0070) 2010; 130 Metchnikoff (10.1016/j.ejca.2015.06.110_b0215) 2012; 67 Boussemart (10.1016/j.ejca.2015.06.110_b0135) 2013; 24 Goette (10.1016/j.ejca.2015.06.110_b0290) 1980; 2 Euvrard (10.1016/j.ejca.2015.06.110_b0270) 1995; 33 Birch-Johansen (10.1016/j.ejca.2015.06.110_b0065) 2010; 127 10.1016/j.ejca.2015.06.110_b0020 No authors listed (10.1016/j.ejca.2015.06.110_b0495) 1976; 1 Lansbury (10.1016/j.ejca.2015.06.110_b0320) 2013; 347 Nijsten (10.1016/j.ejca.2015.06.110_b0480) 2003; 49 Heath (10.1016/j.ejca.2015.06.110_b0505) 2013; 85 Evans (10.1016/j.ejca.2015.06.110_b0185) 1980; 45 Brougham (10.1016/j.ejca.2015.06.110_b0240) 2012; 106 Audet (10.1016/j.ejca.2015.06.110_b0360) 2004; 26 Zhao (10.1016/j.ejca.2015.06.110_b0150) 2009; 69 Renzi (10.1016/j.ejca.2015.06.110_b0350) 2007; 33 Xiang (10.1016/j.ejca.2015.06.110_b0055) 2014; 150 Brodland (10.1016/j.ejca.2015.06.110_b0305) 1992; 27 Nappi (10.1016/j.ejca.2015.06.110_b0200) 1992; 16 Veness (10.1016/j.ejca.2015.06.110_b0370) 2006; 106 |
| References_xml | – volume: 30 start-page: 633 year: 1994 end-page: 636 ident: b0365 article-title: Adjuvant radiotherapy after excision of cutaneous squamous cell carcinoma publication-title: J Am Acad Dermatol – volume: 24 start-page: 5531 year: 2006 ident: b0500 article-title: Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin publication-title: J Clin Oncol – volume: 65 start-page: 1390 year: 2012 end-page: 1395 ident: b0245 article-title: Re-excision of incompletely excised cutaneous squamous cell carcinoma: histological findings influence prognosis publication-title: J Plast Reconstr Aesthet Surg – volume: 48 start-page: 2046 year: 2012 end-page: 2053 ident: b0080 article-title: Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008 publication-title: Eur J Cancer – volume: 33 start-page: 364 year: 2007 end-page: 369 ident: b0350 article-title: Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature publication-title: Eur J Surg Oncol – volume: 106 start-page: 811 year: 2012 end-page: 815 ident: b0240 article-title: The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors publication-title: J Surg Oncol – volume: 150 start-page: 1063 year: 2014 end-page: 1071 ident: b0055 article-title: Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships publication-title: JAMA Dermatol – volume: 85 start-page: 1275 year: 2013 end-page: 1281 ident: b0505 article-title: Phase 1 study of erlotinib plus radiation therapy with advanced cutaneous squamous cell carcinoma publication-title: Int J Radiat Oncol Phys – volume: 139 start-page: 3 year: 2003 ident: b0275 article-title: Defining the course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study publication-title: Arch Dermatol – volume: 25 start-page: 77 year: 2013 end-page: 82 ident: b0330 article-title: Current management strategies for verrucous hyperkeratosis and verrucous carcinoma publication-title: Oral Maxillofac Surg Clin North Am – volume: 49 start-page: 644 year: 2003 end-page: 650 ident: b0480 article-title: Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study publication-title: J Am Acad Dermatol – volume: 116 start-page: 224 year: 2001 end-page: 229 ident: b0120 article-title: Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma publication-title: J Invest Dermatol – volume: 165 start-page: 1169 year: 2011 end-page: 1177 ident: b0390 article-title: Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature publication-title: Br J Dermatol – volume: 166 start-page: 1069 year: 2012 end-page: 1080 ident: b0040 article-title: A systematic review of worldwide incidence of nonmelanoma skin cancer publication-title: Br J Dermatol – volume: 65 start-page: 263 year: 2011 end-page: 279 ident: b0265 article-title: Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients publication-title: J Am Acad Dermatol – volume: 23 start-page: 8646 year: 2005 end-page: 8654 ident: b0450 article-title: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study publication-title: J Clin Oncol – volume: 122 start-page: 464 year: 2012 end-page: 472 ident: b0140 article-title: From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma publication-title: J Clin Invest – volume: 149 start-page: 402 year: 2013 end-page: 410 ident: b0220 article-title: Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system publication-title: JAMA Dermatol – volume: 118 start-page: 2128 year: 2012 end-page: 2137 ident: b0285 article-title: Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251) publication-title: Cancer – volume: 36 start-page: 422 year: 2013 end-page: 429 ident: b0175 article-title: Keratoacanthoma clinical behavior: a systematic review publication-title: Am J Dermatopathol – volume: 69 start-page: 9439 year: 2009 end-page: 9447 ident: b0150 article-title: Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53 publication-title: Cancer Res – volume: 106 start-page: 2389 year: 2006 end-page: 2396 ident: b0370 article-title: High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease publication-title: Cancer – volume: 134 start-page: 303 year: 1999 end-page: 307 ident: b0425 article-title: Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study publication-title: Arch Surg – volume: 24 start-page: 618 year: 2001 end-page: 622 ident: b0415 article-title: Gemcitabine, cisplatin and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study publication-title: Am J Clin Oncol – volume: 11 start-page: 1462 year: 2012 end-page: 1467 ident: b0465 article-title: The paradigm shift in treating actinic keratosis: a comprehensive strategy publication-title: J Drugs Dermatol – volume: 52 start-page: 278 year: 2008 end-page: 286 ident: b0325 article-title: The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities publication-title: J Med Imaging Radiat Oncol – volume: 133 start-page: 735 year: 1997 end-page: 740 ident: b0035 article-title: Trends in population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992 publication-title: Arch Dermatol – reference: Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Version I.2013. Available at: < – volume: 2 start-page: 212 year: 1980 end-page: 216 ident: b0290 article-title: Successful treatment of keratoacanthoma with intralesional fluorouracil publication-title: J Am Acad Dermatol – volume: 146 start-page: 283 year: 2010 end-page: 287 ident: b0025 article-title: Incidence estimate of nonmelanoma skin cancer in the United States, 2006 publication-title: Arch Dermatol – volume: 169 start-page: 502 year: 2013 end-page: 518 ident: b0165 article-title: The natural history of actinic keratosis: a systematic review publication-title: Br J Dermatol – volume: 29 start-page: 3419 year: 2011 end-page: 3426 ident: b0445 article-title: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin publication-title: J Clin Oncol – year: 2009 ident: b0205 article-title: TNM classification of malignant tumors (UICC International Union Against Cancer) – volume: 23 start-page: 749 year: 2013 end-page: 757 ident: b0340 article-title: Post radiation skin tumors: basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy publication-title: Eur J Dermatol – volume: 67 start-page: 829 year: 2012 end-page: 835 ident: b0215 article-title: The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients publication-title: J Am Acad Dermatol – volume: 66 start-page: 1692 year: 1990 end-page: 1696 ident: b0395 article-title: Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin publication-title: Cancer – volume: 47 start-page: 1 year: 2002 end-page: 17 ident: b0125 article-title: Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management publication-title: J Am Acad Dermatol – volume: 347 start-page: f6153 year: 2013 ident: b0320 article-title: Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies publication-title: BMJ – volume: 367 start-page: 329 year: 2012 end-page: 339 ident: b0490 article-title: Sirolimus and secondary skin-cancer prevention in kidney transplantation publication-title: N Engl J Med – volume: 164 start-page: 822 year: 2011 end-page: 829 ident: b0060 article-title: Geographical, urban/rural and socioeconomic variations in nonmelanoma skin cancer incidence: a population-based study in Ireland publication-title: Br J Dermatol – volume: 56 start-page: 989 year: 2007 end-page: 993 ident: b0295 article-title: Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature publication-title: J Am Acad Dermatol – volume: 127 start-page: 2190 year: 2010 end-page: 2198 ident: b0065 article-title: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: rapid incidence increase among young Danish women publication-title: Int J Cancer – volume: 26 start-page: 727 year: 2004 end-page: 732 ident: b0360 article-title: Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome publication-title: Head Neck – year: 2009 ident: b0210 article-title: AJCC cancer staging manual – volume: 9 start-page: 713 year: 2008 end-page: 720 ident: b0235 article-title: Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study publication-title: Lancet Oncol – volume: 10 start-page: 51 year: 2012 end-page: 58 ident: b0005 article-title: Brief guidelines – cutaneous squamous cell carcinoma publication-title: JDDG – volume: 25 start-page: 1205 year: 2005 end-page: 1210 ident: b0440 article-title: Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin publication-title: Anticancer Res – volume: 184 start-page: 6 year: 2006 end-page: 10 ident: b0045 article-title: Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985 publication-title: Med J Aust – volume: 169 start-page: 1310 year: 2013 end-page: 1313 ident: b0485 article-title: Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors publication-title: Br J Dermatol – volume: 149 start-page: 541 year: 2013 end-page: 547 ident: b0230 article-title: Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study publication-title: JAMA Dermatol – volume: 27 start-page: 241 year: 1992 end-page: 248 ident: b0305 article-title: Surgical margins for excision of primary cutaneous squamous cell carcinoma publication-title: J Am Acad Dermatol – volume: 25 start-page: 1272 year: 2007 end-page: 1276 ident: b0420 article-title: Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups publication-title: J Clin Oncol – volume: 262 start-page: 2097 year: 1989 end-page: 2100 ident: b0030 article-title: The emerging epidemic of melanoma and squamous cell skin cancer publication-title: JAMA – volume: 79 start-page: 915 year: 1997 end-page: 919 ident: b0195 article-title: Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer publication-title: Cancer – volume: 23 start-page: 651 year: 2010 end-page: 661 ident: b0385 article-title: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach publication-title: Dermatol Ther – volume: 348 start-page: 1681 year: 2003 end-page: 1691 ident: b0260 article-title: Skin cancers after organ transplantation publication-title: N Engl J Med – volume: 150 start-page: 19 year: 2013 end-page: 24 ident: b0355 article-title: Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American joint committee on cancer criteria and a proposed alternative system publication-title: JAMA Dermatol – volume: 38 start-page: 179 year: 1998 end-page: 185 ident: b0110 article-title: Cutaneous manifestations of chronic arsenicism: review of seventeen cases publication-title: J Am Acad Dermatol – volume: 129 start-page: 2766 year: 2009 end-page: 2771 ident: b0460 article-title: Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings publication-title: J Invest Dermatol – volume: 25 start-page: 1974 year: 2007 end-page: 1978 ident: b0380 article-title: Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma publication-title: J Clin Oncol – volume: 25 start-page: 16519 year: 2007 ident: b0515 article-title: Squamous carcinoma of the skin responding to erlotinib: Three cases publication-title: J Clin Oncol – volume: 8 start-page: 342 year: 1990 end-page: 346 ident: b0405 article-title: Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy publication-title: J Clin Oncol – volume: 148 start-page: 542 year: 1984 end-page: 547 ident: b0250 article-title: Perineural invasion in squamous cell skin carcinoma of the head and neck publication-title: Am J Surg – volume: 84 start-page: 235 year: 1992 end-page: 241 ident: b0435 article-title: 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin publication-title: J Natl Cancer Inst – volume: 133 start-page: 1188 year: 2013 ident: b0310 article-title: Tumor recurrence 5 publication-title: J Invest Dermatol – volume: 1 start-page: 795 year: 1988 end-page: 797 ident: b0160 article-title: Malignant transformation of solar keratoses to squamous cell carcinoma publication-title: Lancet – volume: 69 start-page: 8926 year: 2009 end-page: 8931 ident: b0170 article-title: Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma publication-title: Cancer Res – volume: 146 start-page: 18 year: 2002 end-page: 25 ident: b0015 article-title: Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma publication-title: Br J Dermatol – volume: 54 start-page: 290 year: 2006 end-page: 300 ident: b0130 article-title: Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series publication-title: J Am Acad Dermatol – volume: 149 start-page: 35 year: 2013 end-page: 41 ident: b0255 article-title: Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study publication-title: JAMA Dermatol – volume: 19 start-page: 286 year: 1992 end-page: 293 ident: b0190 article-title: Spindle cell neoplasms coexpressing cytokeratin and vimentin (metaplastic squamous cell carcinoma) publication-title: J Cutan Pathol – volume: 23 start-page: 181 year: 2000 end-page: 184 ident: b0400 article-title: Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged publication-title: Am J Clin Oncol – volume: 1 start-page: 188 year: 1976 end-page: 190 ident: b0495 article-title: Bleomycin in advanced squamous cell carcinoma: a random controlled trial. Report of Medical Research Council Working Party on Bleomycin publication-title: Br Med J – volume: 167 start-page: 1 year: 2012 end-page: 13 ident: b0090 article-title: Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study publication-title: Br J Dermatol – volume: 45 start-page: 2687 year: 1980 end-page: 2697 ident: b0185 article-title: Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases publication-title: Cancer – volume: 3 start-page: 257 year: 2012 end-page: 261 ident: b0510 article-title: Cetuximab in refractory skin cancer treatment publication-title: J Cancer – volume: 32 start-page: 39 year: 2003 end-page: 42 ident: b0225 article-title: The diagnostic value of ultrasonography to detect occult lymph node involvement at different levels in patients with squamous cell carcinoma in the maxillofacial region publication-title: Int J Oral Maxillofac Surg – volume: 4 start-page: 462 year: 2007 end-page: 469 ident: b0335 article-title: Management of nonmelanoma skin cancer in 2007 publication-title: Nat Clin Pract Oncol – volume: 67 start-page: 2030 year: 1991 end-page: 2032 ident: b0410 article-title: Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin publication-title: Cancer – volume: 16 start-page: 429 year: 1992 end-page: 438 ident: b0200 article-title: Pseudovascular adenoid squamous cell carcinoma of the skin. A neoplasm that may be mistaken for angiosarcoma publication-title: Am J Surg Pathol – volume: 25 start-page: 1 year: 2011 end-page: 51 ident: b0010 article-title: Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions publication-title: J Eur Acad Dermatol Venereol – volume: 26 start-page: 1657 year: 2005 end-page: 1667 ident: b0145 article-title: Non-melanoma skin cancer: what drives tumor development and progression? publication-title: Carcinogenesis – volume: 33 start-page: 222 year: 1995 end-page: 229 ident: b0270 article-title: Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation publication-title: J Am Acad Dermatol – volume: 20 start-page: 364 year: 2002 end-page: 370 ident: b0430 article-title: Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer publication-title: J Clin Oncol – volume: 14 start-page: e11 year: 2013 end-page: e18 ident: b0180 article-title: Cutaneous toxicities of RAF inhibitors publication-title: Lancet Oncol – volume: 41 start-page: 316 year: 2014 end-page: 318 ident: b0315 article-title: Technique for histological control of surgical margins in lip cancer publication-title: J Dermatol – volume: 68 start-page: 957 year: 2013 end-page: 966 ident: b0050 article-title: Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012 publication-title: J Am Acad Dermatol – volume: 24 start-page: 1691 year: 2013 end-page: 1697 ident: b0135 article-title: Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients publication-title: Ann Oncol – volume: 69 start-page: 253 year: 2013 end-page: 261 ident: b0300 article-title: A retrospective study of squamous cell carcinoma of the nail unit diagnosed in a Belgian general hospital over a 15-year period publication-title: J Am Acad Dermatol – volume: 139 start-page: 407 year: 2009 end-page: 415 ident: b0475 article-title: Swiss clinical practice guidelines for skin cancer in organ transplant recipients publication-title: Swiss Med Wkly – volume: 32 start-page: 1309 year: 2006 end-page: 1321 ident: b0345 article-title: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature publication-title: Dermatol Surg – volume: 73 start-page: 1612 year: 1996 end-page: 1614 ident: b0100 article-title: Non-solar ultraviolet radiation and the risk of basal and squamous cell skin cancer publication-title: Br J Cancer – volume: 18 start-page: 776 year: 2007 end-page: 784 ident: b0105 article-title: Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure publication-title: Epidemiology – volume: 130 start-page: 1323 year: 2010 end-page: 1328 ident: b0070 article-title: Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases publication-title: J Invest Dermatol – volume: 149 start-page: 1200 year: 2003 end-page: 1206 ident: b0075 article-title: Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumor stages and localization (epidemiology of skin cancer) publication-title: Br J Dermatol – volume: 294 start-page: 681 year: 2005 end-page: 690 ident: b0085 article-title: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 publication-title: JAMA – volume: 109 start-page: 1053 year: 2007 end-page: 1059 ident: b0375 article-title: What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? publication-title: Cancer – volume: 18 start-page: 137 year: 2004 end-page: 141 ident: b0095 article-title: Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (North-Eastern Spain) 1998–2000: a hospital-based survey publication-title: J Eur Acad Dermatol Venereol – reference: >. – volume: 16 start-page: 599 year: 2006 end-page: 606 ident: b0280 article-title: Guidelines for the management of actinic keratoses publication-title: Eur J Dermatol – volume: 26 start-page: 1063 year: 2012 end-page: 1066 ident: b0470 article-title: Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology publication-title: J Eur Acad Dermatol Venereol – volume: 18 start-page: 1435 year: 2012 end-page: 1446 ident: b0455 article-title: A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck publication-title: Clin Cancer Res – volume: 53 start-page: 585 year: 1993 end-page: 590 ident: b0115 article-title: Trends in non-melanocytic skin cancer treated in Australia: the second national survey publication-title: Int J Cancer – volume: 91 start-page: 355 year: 2004 end-page: 358 ident: b0155 article-title: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website publication-title: Br J Cancer – volume: 49 start-page: 644 year: 2003 ident: 10.1016/j.ejca.2015.06.110_b0480 article-title: Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study publication-title: J Am Acad Dermatol doi: 10.1067/S0190-9622(03)01587-1 – volume: 150 start-page: 19 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0355 article-title: Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American joint committee on cancer criteria and a proposed alternative system publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2013.6675 – volume: 169 start-page: 1310 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0485 article-title: Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors publication-title: Br J Dermatol doi: 10.1111/bjd.12519 – volume: 146 start-page: 283 year: 2010 ident: 10.1016/j.ejca.2015.06.110_b0025 article-title: Incidence estimate of nonmelanoma skin cancer in the United States, 2006 publication-title: Arch Dermatol doi: 10.1001/archdermatol.2010.19 – volume: 36 start-page: 422 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0175 article-title: Keratoacanthoma clinical behavior: a systematic review publication-title: Am J Dermatopathol doi: 10.1097/DAD.0000000000000031 – volume: 65 start-page: 1390 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0245 article-title: Re-excision of incompletely excised cutaneous squamous cell carcinoma: histological findings influence prognosis publication-title: J Plast Reconstr Aesthet Surg doi: 10.1016/j.bjps.2012.04.031 – volume: 166 start-page: 1069 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0040 article-title: A systematic review of worldwide incidence of nonmelanoma skin cancer publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2012.10830.x – volume: 69 start-page: 9439 year: 2009 ident: 10.1016/j.ejca.2015.06.110_b0150 article-title: Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-2976 – volume: 53 start-page: 585 year: 1993 ident: 10.1016/j.ejca.2015.06.110_b0115 article-title: Trends in non-melanocytic skin cancer treated in Australia: the second national survey publication-title: Int J Cancer doi: 10.1002/ijc.2910530410 – volume: 68 start-page: 957 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0050 article-title: Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2012.11.037 – volume: 18 start-page: 137 year: 2004 ident: 10.1016/j.ejca.2015.06.110_b0095 article-title: Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (North-Eastern Spain) 1998–2000: a hospital-based survey publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2004.00829.x – volume: 1 start-page: 188 year: 1976 ident: 10.1016/j.ejca.2015.06.110_b0495 article-title: Bleomycin in advanced squamous cell carcinoma: a random controlled trial. Report of Medical Research Council Working Party on Bleomycin publication-title: Br Med J doi: 10.1136/bmj.1.6003.188 – volume: 367 start-page: 329 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0490 article-title: Sirolimus and secondary skin-cancer prevention in kidney transplantation publication-title: N Engl J Med doi: 10.1056/NEJMoa1204166 – volume: 262 start-page: 2097 year: 1989 ident: 10.1016/j.ejca.2015.06.110_b0030 article-title: The emerging epidemic of melanoma and squamous cell skin cancer publication-title: JAMA doi: 10.1001/jama.1989.03430150065027 – volume: 10 start-page: 51 issue: Suppl. 6 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0005 article-title: Brief guidelines – cutaneous squamous cell carcinoma publication-title: JDDG – volume: 91 start-page: 355 year: 2004 ident: 10.1016/j.ejca.2015.06.110_b0155 article-title: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601894 – volume: 106 start-page: 2389 year: 2006 ident: 10.1016/j.ejca.2015.06.110_b0370 article-title: High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease publication-title: Cancer doi: 10.1002/cncr.21898 – volume: 67 start-page: 829 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0215 article-title: The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2012.01.010 – volume: 8 start-page: 342 year: 1990 ident: 10.1016/j.ejca.2015.06.110_b0405 article-title: Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy publication-title: J Clin Oncol doi: 10.1200/JCO.1990.8.2.342 – volume: 25 start-page: 1205 year: 2005 ident: 10.1016/j.ejca.2015.06.110_b0440 article-title: Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin publication-title: Anticancer Res – volume: 149 start-page: 541 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0230 article-title: Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2013.2139 – volume: 23 start-page: 8646 year: 2005 ident: 10.1016/j.ejca.2015.06.110_b0450 article-title: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.4646 – volume: 133 start-page: 735 year: 1997 ident: 10.1016/j.ejca.2015.06.110_b0035 article-title: Trends in population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992 publication-title: Arch Dermatol doi: 10.1001/archderm.1997.03890420073008 – volume: 130 start-page: 1323 year: 2010 ident: 10.1016/j.ejca.2015.06.110_b0070 article-title: Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases publication-title: J Invest Dermatol doi: 10.1038/jid.2009.426 – volume: 9 start-page: 713 year: 2008 ident: 10.1016/j.ejca.2015.06.110_b0235 article-title: Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70178-5 – volume: 26 start-page: 727 year: 2004 ident: 10.1016/j.ejca.2015.06.110_b0360 article-title: Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome publication-title: Head Neck doi: 10.1002/hed.20048 – volume: 23 start-page: 651 year: 2010 ident: 10.1016/j.ejca.2015.06.110_b0385 article-title: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach publication-title: Dermatol Ther doi: 10.1111/j.1529-8019.2010.01370.x – volume: 133 start-page: 1188 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0310 article-title: Tumor recurrence 5years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma publication-title: J Invest Dermatol doi: 10.1038/jid.2012.403 – volume: 85 start-page: 1275 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0505 article-title: Phase 1 study of erlotinib plus radiation therapy with advanced cutaneous squamous cell carcinoma publication-title: Int J Radiat Oncol Phys doi: 10.1016/j.ijrobp.2012.09.030 – volume: 16 start-page: 429 year: 1992 ident: 10.1016/j.ejca.2015.06.110_b0200 article-title: Pseudovascular adenoid squamous cell carcinoma of the skin. A neoplasm that may be mistaken for angiosarcoma publication-title: Am J Surg Pathol doi: 10.1097/00000478-199205000-00001 – volume: 52 start-page: 278 year: 2008 ident: 10.1016/j.ejca.2015.06.110_b0325 article-title: The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities publication-title: J Med Imaging Radiat Oncol doi: 10.1111/j.1440-1673.2008.01956.x – volume: 2 start-page: 212 year: 1980 ident: 10.1016/j.ejca.2015.06.110_b0290 article-title: Successful treatment of keratoacanthoma with intralesional fluorouracil publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(80)80007-7 – volume: 67 start-page: 2030 year: 1991 ident: 10.1016/j.ejca.2015.06.110_b0410 article-title: Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin publication-title: Cancer doi: 10.1002/1097-0142(19910415)67:8<2030::AID-CNCR2820670803>3.0.CO;2-K – volume: 20 start-page: 364 year: 2002 ident: 10.1016/j.ejca.2015.06.110_b0430 article-title: Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.2.364 – volume: 146 start-page: 18 year: 2002 ident: 10.1016/j.ejca.2015.06.110_b0015 article-title: Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma publication-title: Br J Dermatol doi: 10.1046/j.0007-0963.2001.04615.x – volume: 169 start-page: 502 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0165 article-title: The natural history of actinic keratosis: a systematic review publication-title: Br J Dermatol doi: 10.1111/bjd.12420 – volume: 33 start-page: 222 year: 1995 ident: 10.1016/j.ejca.2015.06.110_b0270 article-title: Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation publication-title: J Am Acad Dermatol doi: 10.1016/0190-9622(95)90239-2 – volume: 347 start-page: f6153 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0320 article-title: Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies publication-title: BMJ doi: 10.1136/bmj.f6153 – volume: 30 start-page: 633 year: 1994 ident: 10.1016/j.ejca.2015.06.110_b0365 article-title: Adjuvant radiotherapy after excision of cutaneous squamous cell carcinoma publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(94)70073-7 – volume: 69 start-page: 8926 year: 2009 ident: 10.1016/j.ejca.2015.06.110_b0170 article-title: Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-1186 – volume: 32 start-page: 39 year: 2003 ident: 10.1016/j.ejca.2015.06.110_b0225 article-title: The diagnostic value of ultrasonography to detect occult lymph node involvement at different levels in patients with squamous cell carcinoma in the maxillofacial region publication-title: Int J Oral Maxillofac Surg doi: 10.1054/ijom.2002.0326 – volume: 24 start-page: 618 year: 2001 ident: 10.1016/j.ejca.2015.06.110_b0415 article-title: Gemcitabine, cisplatin and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study publication-title: Am J Clin Oncol doi: 10.1097/00000421-200112000-00019 – volume: 29 start-page: 3419 year: 2011 ident: 10.1016/j.ejca.2015.06.110_b0445 article-title: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin publication-title: J Clin Oncol doi: 10.1200/JCO.2010.34.1735 – volume: 25 start-page: 77 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0330 article-title: Current management strategies for verrucous hyperkeratosis and verrucous carcinoma publication-title: Oral Maxillofac Surg Clin North Am doi: 10.1016/j.coms.2012.11.008 – volume: 84 start-page: 235 year: 1992 ident: 10.1016/j.ejca.2015.06.110_b0435 article-title: 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin publication-title: J Natl Cancer Inst doi: 10.1093/jnci/84.4.235 – volume: 23 start-page: 749 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0340 article-title: Post radiation skin tumors: basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy publication-title: Eur J Dermatol doi: 10.1684/ejd.2013.2106 – volume: 33 start-page: 364 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0350 article-title: Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2006.10.017 – volume: 127 start-page: 2190 year: 2010 ident: 10.1016/j.ejca.2015.06.110_b0065 article-title: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: rapid incidence increase among young Danish women publication-title: Int J Cancer doi: 10.1002/ijc.25411 – volume: 69 start-page: 253 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0300 article-title: A retrospective study of squamous cell carcinoma of the nail unit diagnosed in a Belgian general hospital over a 15-year period publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2013.02.008 – volume: 18 start-page: 1435 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0455 article-title: A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1951 – volume: 48 start-page: 2046 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0080 article-title: Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.01.003 – volume: 79 start-page: 915 year: 1997 ident: 10.1016/j.ejca.2015.06.110_b0195 article-title: Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19970301)79:5<915::AID-CNCR7>3.0.CO;2-A – ident: 10.1016/j.ejca.2015.06.110_b0020 – volume: 32 start-page: 1309 year: 2006 ident: 10.1016/j.ejca.2015.06.110_b0345 article-title: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature publication-title: Dermatol Surg – volume: 25 start-page: 1974 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0380 article-title: Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.9873 – volume: 25 start-page: 16519 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0515 article-title: Squamous carcinoma of the skin responding to erlotinib: Three cases publication-title: J Clin Oncol doi: 10.1200/jco.2007.25.18_suppl.16519 – volume: 3 start-page: 257 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0510 article-title: Cetuximab in refractory skin cancer treatment publication-title: J Cancer doi: 10.7150/jca.3491 – volume: 148 start-page: 542 year: 1984 ident: 10.1016/j.ejca.2015.06.110_b0250 article-title: Perineural invasion in squamous cell skin carcinoma of the head and neck publication-title: Am J Surg doi: 10.1016/0002-9610(84)90385-4 – volume: 149 start-page: 402 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0220 article-title: Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2013.2456 – volume: 25 start-page: 1 year: 2011 ident: 10.1016/j.ejca.2015.06.110_b0010 article-title: Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2011.04296.x – volume: 150 start-page: 1063 year: 2014 ident: 10.1016/j.ejca.2015.06.110_b0055 article-title: Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2014.762 – volume: 139 start-page: 407 year: 2009 ident: 10.1016/j.ejca.2015.06.110_b0475 article-title: Swiss clinical practice guidelines for skin cancer in organ transplant recipients publication-title: Swiss Med Wkly – volume: 24 start-page: 5531 year: 2006 ident: 10.1016/j.ejca.2015.06.110_b0500 article-title: Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin publication-title: J Clin Oncol doi: 10.1200/jco.2006.24.18_suppl.5531 – volume: 149 start-page: 35 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0255 article-title: Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2013.746 – volume: 19 start-page: 286 year: 1992 ident: 10.1016/j.ejca.2015.06.110_b0190 article-title: Spindle cell neoplasms coexpressing cytokeratin and vimentin (metaplastic squamous cell carcinoma) publication-title: J Cutan Pathol doi: 10.1111/j.1600-0560.1992.tb01364.x – volume: 26 start-page: 1657 year: 2005 ident: 10.1016/j.ejca.2015.06.110_b0145 article-title: Non-melanoma skin cancer: what drives tumor development and progression? publication-title: Carcinogenesis doi: 10.1093/carcin/bgi123 – volume: 348 start-page: 1681 year: 2003 ident: 10.1016/j.ejca.2015.06.110_b0260 article-title: Skin cancers after organ transplantation publication-title: N Engl J Med doi: 10.1056/NEJMra022137 – volume: 129 start-page: 2766 year: 2009 ident: 10.1016/j.ejca.2015.06.110_b0460 article-title: Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings publication-title: J Invest Dermatol doi: 10.1038/jid.2009.141 – volume: 24 start-page: 1691 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0135 article-title: Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients publication-title: Ann Oncol doi: 10.1093/annonc/mdt015 – volume: 122 start-page: 464 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0140 article-title: From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma publication-title: J Clin Invest doi: 10.1172/JCI57415 – volume: 45 start-page: 2687 year: 1980 ident: 10.1016/j.ejca.2015.06.110_b0185 article-title: Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases publication-title: Cancer doi: 10.1002/1097-0142(19800515)45:10<2687::AID-CNCR2820451034>3.0.CO;2-R – volume: 27 start-page: 241 year: 1992 ident: 10.1016/j.ejca.2015.06.110_b0305 article-title: Surgical margins for excision of primary cutaneous squamous cell carcinoma publication-title: J Am Acad Dermatol doi: 10.1016/0190-9622(92)70178-I – volume: 4 start-page: 462 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0335 article-title: Management of nonmelanoma skin cancer in 2007 publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc0883 – volume: 167 start-page: 1 issue: Suppl 2 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0090 article-title: Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2012.11081.x – volume: 116 start-page: 224 year: 2001 ident: 10.1016/j.ejca.2015.06.110_b0120 article-title: Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma publication-title: J Invest Dermatol doi: 10.1046/j.1523-1747.2001.01224.x – volume: 38 start-page: 179 issue: 2 Pt 1 year: 1998 ident: 10.1016/j.ejca.2015.06.110_b0110 article-title: Cutaneous manifestations of chronic arsenicism: review of seventeen cases publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(98)70596-1 – volume: 25 start-page: 1272 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0420 article-title: Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.2759 – volume: 164 start-page: 822 year: 2011 ident: 10.1016/j.ejca.2015.06.110_b0060 article-title: Geographical, urban/rural and socioeconomic variations in nonmelanoma skin cancer incidence: a population-based study in Ireland publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10238.x – volume: 65 start-page: 263 year: 2011 ident: 10.1016/j.ejca.2015.06.110_b0265 article-title: Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2010.11.063 – volume: 23 start-page: 181 year: 2000 ident: 10.1016/j.ejca.2015.06.110_b0400 article-title: Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged publication-title: Am J Clin Oncol doi: 10.1097/00000421-200004000-00015 – volume: 73 start-page: 1612 year: 1996 ident: 10.1016/j.ejca.2015.06.110_b0100 article-title: Non-solar ultraviolet radiation and the risk of basal and squamous cell skin cancer publication-title: Br J Cancer doi: 10.1038/bjc.1996.303 – volume: 18 start-page: 776 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0105 article-title: Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure publication-title: Epidemiology doi: 10.1097/EDE.0b013e3181567ebe – volume: 47 start-page: 1 year: 2002 ident: 10.1016/j.ejca.2015.06.110_b0125 article-title: Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management publication-title: J Am Acad Dermatol doi: 10.1067/mjd.2002.125579 – volume: 66 start-page: 1692 year: 1990 ident: 10.1016/j.ejca.2015.06.110_b0395 article-title: Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin publication-title: Cancer doi: 10.1002/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y – volume: 54 start-page: 290 year: 2006 ident: 10.1016/j.ejca.2015.06.110_b0130 article-title: Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2005.10.049 – volume: 56 start-page: 989 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0295 article-title: Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2006.12.017 – volume: 1 start-page: 795 issue: 8589 year: 1988 ident: 10.1016/j.ejca.2015.06.110_b0160 article-title: Malignant transformation of solar keratoses to squamous cell carcinoma publication-title: Lancet doi: 10.1016/S0140-6736(88)91658-3 – volume: 11 start-page: 1462 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0465 article-title: The paradigm shift in treating actinic keratosis: a comprehensive strategy publication-title: J Drugs Dermatol – volume: 184 start-page: 6 year: 2006 ident: 10.1016/j.ejca.2015.06.110_b0045 article-title: Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985 publication-title: Med J Aust doi: 10.5694/j.1326-5377.2006.tb00086.x – year: 2009 ident: 10.1016/j.ejca.2015.06.110_b0210 – volume: 106 start-page: 811 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0240 article-title: The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors publication-title: J Surg Oncol doi: 10.1002/jso.23155 – volume: 41 start-page: 316 year: 2014 ident: 10.1016/j.ejca.2015.06.110_b0315 article-title: Technique for histological control of surgical margins in lip cancer publication-title: J Dermatol doi: 10.1111/1346-8138.12424 – volume: 149 start-page: 1200 year: 2003 ident: 10.1016/j.ejca.2015.06.110_b0075 article-title: Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumor stages and localization (epidemiology of skin cancer) publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2003.05554.x – volume: 118 start-page: 2128 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0285 article-title: Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251) publication-title: Cancer doi: 10.1002/cncr.26374 – volume: 109 start-page: 1053 year: 2007 ident: 10.1016/j.ejca.2015.06.110_b0375 article-title: What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? publication-title: Cancer doi: 10.1002/cncr.22509 – volume: 139 start-page: 3 year: 2003 ident: 10.1016/j.ejca.2015.06.110_b0275 article-title: Defining the course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study publication-title: Arch Dermatol doi: 10.1001/archderm.139.3.301 – volume: 165 start-page: 1169 year: 2011 ident: 10.1016/j.ejca.2015.06.110_b0390 article-title: Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10524.x – year: 2009 ident: 10.1016/j.ejca.2015.06.110_b0205 – volume: 26 start-page: 1063 year: 2012 ident: 10.1016/j.ejca.2015.06.110_b0470 article-title: Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2011.04432.x – volume: 16 start-page: 599 year: 2006 ident: 10.1016/j.ejca.2015.06.110_b0280 article-title: Guidelines for the management of actinic keratoses publication-title: Eur J Dermatol – volume: 294 start-page: 681 year: 2005 ident: 10.1016/j.ejca.2015.06.110_b0085 article-title: Incidence of basal cell and squamous cell carcinomas in a population younger than 40years publication-title: JAMA doi: 10.1001/jama.294.6.681 – volume: 14 start-page: e11 year: 2013 ident: 10.1016/j.ejca.2015.06.110_b0180 article-title: Cutaneous toxicities of RAF inhibitors publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70413-8 – volume: 134 start-page: 303 year: 1999 ident: 10.1016/j.ejca.2015.06.110_b0425 article-title: Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study publication-title: Arch Surg doi: 10.1001/archsurg.134.3.303 |
| SSID | ssj0007840 |
| Score | 2.6279614 |
| SecondaryResourceType | review_article |
| Snippet | Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique... Abstract Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in Caucasian populations, accounting for 20% of all cutaneous malignancies.... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1989 |
| SubjectTerms | Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - epidemiology Carcinoma, Squamous Cell - therapy Consensus Cooperative Behavior Cutaneous squamous cell carcinoma Dermatology - standards Diagnosis Europe Follow up Hematology, Oncology and Palliative Medicine Humans Interdisciplinary Communication International Cooperation Management Medical Oncology - standards Neoplasm Staging Pathology Predictive Value of Tests Prognosis Radiation therapy Risk Factors Skin Neoplasms - diagnosis Skin Neoplasms - epidemiology Skin Neoplasms - therapy Surgical excision Systemic treatment Treatment Outcome |
| Title | Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0959804915006255 https://www.clinicalkey.es/playcontent/1-s2.0-S0959804915006255 https://dx.doi.org/10.1016/j.ejca.2015.06.110 https://www.ncbi.nlm.nih.gov/pubmed/26219687 https://www.proquest.com/docview/1706576411 |
| Volume | 51 |
| WOSCitedRecordID | wos000360081300017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DiFeEHfKZTISb1NQLk6c8lbBEKAxITFQ3yzHcaZWXVqattoL_4mfyDnxZe1oBzzwElWOnSg9X3wu-fyZkJchYwlnaRzESuYBS8oqkEkhA64hlOOyTFgrpvPtmJ-c5MNh_3On89OthVlNeF3nFxf92X81NbSBsXHp7D-Y218UGuA3GB2OYHY4_pXh3xry3MiIL18SyVttiJVs6erN96XEnP8Q6_aoTq1G9fRcOsJAg3t0JYNDX6pXyLmum2UToNcrW5GJ-caC3rMl6mW5j_TbSv027FUIs3mrDwUuaq0Q0erkjs4M7c-vu_H8IDkvDGlxIpc-DzjWhW0F79ks1ni8k5U2-Gk_cazXNqLUk7fANZn5OOfQkqcbE7ZVqLXAZGvTLxLAtvoFU6IYv9JjhWJTUYqirZEh1K5hYnbegiLOYB7PbCCwqcbtTu2R_Zin_bxL9gcfjoYfvffnkDHbxVmGR3j1lig_bS-yKxbaleu0Mc_pHXLbJit0YEB2l3R0fY_c_GTpGPfJD481CsaiHmt0WlGHNeqwRhFr1GMN-wDWKGLtNXVIoVeQRn9DGvVIe0C-vjs6ffM-sPt5BCrl8SJArX9Z6TirkqxkRdWP-ixSPIOoNQ9LDol3kfGiKjNWxixNKikzXVZKQURa6Jir5CHp1tNaPyY0krEKdT-XTGNXLXmkiwompCIpIOeNeyRy_6xQVuwe91yZCMdqHAs0jEDDiDCDRDjskUM_ZmakXq7tnTiDCbeIGdyuAMRdO4pvG6Ub-x42IhJNLELxBevzOTwKJGxhBnl_j6R-pA2OTdD7xzu-cGgS4DnQ1LLWYHWBwlkpz1gU9cgjAzP_3A6hT3aeeUpuXb6xz0h3MV_q5-SGWi1GzfyA7PFhfmDfjV9xxu2C |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnosis+and+treatment+of+invasive+squamous+cell+carcinoma+of+the+skin%3A+European+consensus-based+interdisciplinary+guideline&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Stratigos%2C+Alexander&rft.au=Garbe%2C+Claus&rft.au=Lebbe%2C+Celeste&rft.au=Malvehy%2C+Josep&rft.date=2015-09-01&rft.eissn=1879-0852&rft.volume=51&rft.issue=14&rft.spage=1989&rft_id=info:doi/10.1016%2Fj.ejca.2015.06.110&rft_id=info%3Apmid%2F26219687&rft.externalDocID=26219687 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09598049%2FS0959804915X00153%2Fcov150h.gif |